Helen Hartley1, Barry Pizer2, Steven Lane3, Christine Sneade1, Rebecca Williams1, Conor Mallucci4, Lisa Bunn5, Ram Kumar6. 1. Physiotherapy Department, Alder Hey Children's NHS Foundation Trust, Liverpool, UK. 2. Oncology Department, Alder Hey Children's NHS Foundation Trust, Liverpool, UK. 3. Department of Biostatistics, University of Liverpool, UK. 4. Department of Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, UK. 5. School of Health Professions, University of Plymouth, UK. 6. Department of Neurology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.
Abstract
BACKGROUND: There is minimal literature specific to motor outcomes in children with posterior fossa tumors (PFTs) despite ataxia being a significant problem in this group. This study aims to report children's physical outcomes following management of PFT and determine which factors affect severity of ataxia and functional limitations. METHODS: Forty-two children aged between 5 and 17 and between 1 and 4 years following surgery for PFT were assessed using the Scale for the Assessment and Rating of Ataxia (SARA), the Brief Ataxia Rating Scale (BARS), and the mobility Pediatric Evaluation of Disability Inventory (PEDI) subscale to determine prevalence and severity of ataxia and a measure of physical function. Analysis was undertaken comparing impact of tumor location, tumor histology, adjuvant treatment, age at diagnosis, presence of preoperative ataxia, and presence of cerebellar mutism syndrome (CMS) on ataxia and physical function scores. RESULTS: Seventy-one percent of children demonstrated a SARA and BARS score greater than 2. A total of 48% of children had a PEDI-m score greater than 90. There was no correlation between age at diagnosis or preoperative ataxia and assessment scores. There was a significant difference in SARA/BARS and PEDI-mobility scores depending on tumor histology, tumor location, and presence of CMS. CONCLUSIONS: A high proportion of children (>1 year) following surgery for PFT continue to present with ataxia. Higher ataxia and lower physical function scores were demonstrated in children with medulloblastoma and midline tumors and those diagnosed with CMS. The high prevalence of ataxia demonstrates the need for further research regarding rehabilitation management in this population.
BACKGROUND: There is minimal literature specific to motor outcomes in children with posterior fossa tumors (PFTs) despite ataxia being a significant problem in this group. This study aims to report children's physical outcomes following management of PFT and determine which factors affect severity of ataxia and functional limitations. METHODS: Forty-two children aged between 5 and 17 and between 1 and 4 years following surgery for PFT were assessed using the Scale for the Assessment and Rating of Ataxia (SARA), the Brief Ataxia Rating Scale (BARS), and the mobility Pediatric Evaluation of Disability Inventory (PEDI) subscale to determine prevalence and severity of ataxia and a measure of physical function. Analysis was undertaken comparing impact of tumor location, tumor histology, adjuvant treatment, age at diagnosis, presence of preoperative ataxia, and presence of cerebellar mutism syndrome (CMS) on ataxia and physical function scores. RESULTS: Seventy-one percent of children demonstrated a SARA and BARS score greater than 2. A total of 48% of children had a PEDI-m score greater than 90. There was no correlation between age at diagnosis or preoperative ataxia and assessment scores. There was a significant difference in SARA/BARS and PEDI-mobility scores depending on tumor histology, tumor location, and presence of CMS. CONCLUSIONS: A high proportion of children (>1 year) following surgery for PFT continue to present with ataxia. Higher ataxia and lower physical function scores were demonstrated in children with medulloblastoma and midline tumors and those diagnosed with CMS. The high prevalence of ataxia demonstrates the need for further research regarding rehabilitation management in this population.
Authors: Raymond K Mulhern; Shawna L Palmer; Thomas E Merchant; Dana Wallace; Mehmet Kocak; Pim Brouwers; Kevin Krull; Murali Chintagumpala; Robyn Stargatt; David M Ashley; Vida L Tyc; Larry Kun; James Boyett; Amar Gajjar Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: A L Albright; R Sposto; E Holmes; P M Zeltzer; J L Finlay; J H Wisoff; M S Berger; R J Packer; I F Pollack Journal: Neurosurgery Date: 2000-10 Impact factor: 4.654
Authors: Kirsten K Ness; Ann C Mertens; Melissa M Hudson; Melanie M Wall; Wendy M Leisenring; Kevin C Oeffinger; Charles A Sklar; Leslie L Robison; James G Gurney Journal: Ann Intern Med Date: 2005-11-01 Impact factor: 51.598
Authors: Brad J Zebrack; James G Gurney; Kevin Oeffinger; John Whitton; Roger J Packer; Ann Mertens; Norman Turk; Robert Castleberry; ZoAnn Dreyer; Leslie L Robison; Lonnie K Zeltzer Journal: J Clin Oncol Date: 2004-03-15 Impact factor: 50.717
Authors: Mathieu Decock; Robin De Wilde; Ruth Van der Looven; Catharine Vander Linden Journal: Int J Environ Res Public Health Date: 2022-06-09 Impact factor: 4.614
Authors: O O Golounina; M G Pavlova; Z E Belaya; E I Kim; I V Glinkina; T B Morgunova; N A Mazerkina; O G Zheludkova; V V Fadeev Journal: Probl Endokrinol (Mosk) Date: 2021-01-08
Authors: Philippe F Paquier; Karin S Walsh; Kimberley M Docking; Helen Hartley; Ram Kumar; Coriene E Catsman-Berrevoets Journal: Childs Nerv Syst Date: 2019-06-20 Impact factor: 1.475
Authors: Helen Hartley; Bernie Carter; Lisa Bunn; Barry Pizer; Steven Lane; Ram Kumar; Elizabeth Cassidy Journal: J Rehabil Med Clin Commun Date: 2019-12-30